Challenges in the US | Plenty to like
The US market is a key area of focus for a company covered here supporting the healthcare sector. As we anticipated, it’s proving a tough market to crack, but hopefully success will come. In the meantime expansion in other overseas markets is looking good and there is also a nice dividend to reward the patient. Read on here for our thoughts on the latest interim results as well as our usual forthright opinions on plenty of other updates, including the usual excellence from one of our Stonking Small Caps.
Client portfolios managed by our associates, Fundamental Asset Management, may hold shares in companies covered here. Fundamental manages a dedicated AIM IHT Income portfolioTristel: still all about US roll-out Tristel (AIM: TSTL), the manufacturer of infection prevention products, announced decent interim results, although sales growth was lower than previous years and the US expansion continues to remain challenging as we reflect here. The Company's core business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand, and for the sporicidal disinfection of environmental surfaces under the Cache brand.…